blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability
Register Forum

2022.02.11

More...
blank News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
FAQ - Register Alert
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP2246067

EP2246067 - Methods to elicit, enhance and sustain immune responses against MHC class I-restricted epitopes, for prophylactic or therapeutic purposes [Right-click to bookmark this link]
StatusNo opposition filed within time limit
Status updated on  22.12.2017
Database last updated on 31.08.2024
FormerThe patent has been granted
Status updated on  13.01.2017
Most recent event   Tooltip06.03.2020Lapse of the patent in a contracting state
New state(s): TR		published on 08.04.2020  [2020/15]
Applicant(s)For all designated states
MannKind Corporation
25134 Rye Canyon Loop, Suite 300
Valencia, CA 91355 / US
[2017/07]
Former [2015/51]For all designated states
MannKind Corporation
25134 Rye Canyon Loop
Valencia CA 91355 / US
Former [2010/44]For all designated states
Mannkind Corporation
28903 North Avenue Paine Valencia
California 91355 / US
Inventor(s)01 / Bot, Adrian Ion
24406 West Gable Ranch Lane
Valencia, CA 91354 / US
02 / Liu, Xiping
6035 Camellia Avenue
Temple City, CA 91780 / US
03 / Smith, Kent, Andrew
2916 Bayshore Avenue
Ventura, CA 93001 / US
 [2017/07]
Former [2011/08]01 / Bot, Adrian Ion
24406 West Gable Ranch Lane
Valencia, CA 91354 / US
02 / Liu, Xiping
6035 Camellia Avenue
Temple City, CA 91780 / US
03 / Smith, Kent, Andrew
2916 Bayshore Avenue
Ventura, CA 93001 / US
Former [2010/44]01 / Bot, Adrian, Ion
27003 Carmelita Drive
Valencia, CA 91355 / US
02 / Liu, Xiping
6035 Camellia Avenue
Temple City, CA 91780 / US
03 / Smith, Kent, Andrew
2916 Bayshore Avenue
Ventura, CA 93001 / US
Representative(s)Neuefeind, Regina
Maiwald GmbH
Elisenhof
Elisenstraße 3
80335 München / DE
[N/P]
Former [2017/07]Neuefeind, Regina
Maiwald Patentanwalts GmbH
Elisenhof
Elisenstrasse 3
80335 München / DE
Former [2010/44]Neuefeind, Regina
Maiwald Patentanwalts GmbH Elisenhof Elisenstrasse 3
80335 München / DE
Application number, filing date10171754.417.06.2004
[2010/44]
Priority number, dateUS20030479393P17.06.2003         Original published format: US 479393 P
[2010/44]
Filing languageEN
Procedural languageEN
PublicationType: A2 Application without search report 
No.:EP2246067
Date:03.11.2010
Language:EN
[2010/44]
Type: A3 Search report 
No.:EP2246067
Date:13.07.2011
[2011/28]
Type: B1 Patent specification 
No.:EP2246067
Date:15.02.2017
Language:EN
[2017/07]
Search report(s)(Supplementary) European search report - dispatched on:EP15.06.2011
ClassificationIPC:A61K39/00, A61P35/00, A61P37/00
[2010/44]
CPC:
A61K39/00 (EP,US); A61K39/0011 (EP,US); A61P25/00 (EP);
A61P31/04 (EP); A61P31/10 (EP); A61P31/12 (EP);
A61P33/02 (EP); A61P35/00 (EP); A61P37/00 (EP);
A61K2039/5154 (EP,US); A61K2039/5156 (EP,US); A61K2039/53 (EP,US);
A61K2039/54 (EP,US); A61K2039/545 (EP,US) (-)
Designated contracting statesAT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HU,   IE,   IT,   LI,   LU,   MC,   NL,   PL,   PT,   RO,   SE,   SI,   SK,   TR [2017/07]
Former [2010/44]AT,  BE,  BG,  CH,  CY,  CZ,  DE,  DK,  EE,  ES,  FI,  FR,  GB,  GR,  HU,  IE,  IT,  LI,  LU,  MC,  NL,  PL,  PT,  RO,  SE,  SI,  SK,  TR 
TitleGerman:Verfahren zur Auslösung, Verstärkung und Aufrechterhaltung von Immunreaktionen gegen eingeschränkte Klasse-I-MHC-epitope für prophylaktische oder therapeutische Zwecke[2010/44]
English:Methods to elicit, enhance and sustain immune responses against MHC class I-restricted epitopes, for prophylactic or therapeutic purposes[2010/44]
French:Procédés destinés à susciter, améliorer et entretenir les réponses immunitaires contre des épitopes limités au CMH de classe I dans des buts prophylactiques ou thérapeutiques[2016/26]
Former [2010/44]Procédés destinés à susciter, améliorer et entretenir les réponses immunitaires contre des épitopes limités au CMH de classe I dans des buts prophylactiques ou thérapeutiques
Examination procedure13.01.2012Amendment by applicant (claims and/or description)
13.01.2012Examination requested  [2012/08]
26.09.2013Despatch of a communication from the examining division (Time limit: M04)
06.02.2014Reply to a communication from the examining division
30.09.2014Despatch of a communication from the examining division (Time limit: M01)
30.10.2014Reply to a communication from the examining division
13.07.2015Communication of intention to grant the patent
23.11.2015Disapproval of the communication of intention to grant the patent by the applicant or resumption of examination proceedings by the EPO
23.11.2015Fee for grant paid
23.11.2015Fee for publishing/printing paid
08.12.2015Despatch of a communication from the examining division (Time limit: M02)
15.02.2016Reply to a communication from the examining division
08.06.2016Communication of intention to grant the patent
16.06.2016Fee for grant paid
16.06.2016Fee for publishing/printing paid
16.06.2016Receipt of the translation of the claim(s)
Parent application(s)   TooltipEP04776760.3  / EP1635863
Divisional application(s)EP10180566.1  / EP2356999
The date of the Examining Division's first communication in respect of the earliest application for which a communication has been issued (EP20040776760) is  03.04.2007
Opposition(s)16.11.2017No opposition filed within time limit [2018/04]
Fees paidRenewal fee
03.08.2010Renewal fee patent year 03
03.08.2010Renewal fee patent year 04
03.08.2010Renewal fee patent year 05
03.08.2010Renewal fee patent year 06
03.08.2010Renewal fee patent year 07
27.06.2011Renewal fee patent year 08
31.03.2012Renewal fee patent year 09
27.06.2013Renewal fee patent year 10
30.06.2014Renewal fee patent year 11
29.06.2015Renewal fee patent year 12
29.12.2016Renewal fee patent year 13
Penalty fee
Additional fee for renewal fee
30.06.201613   M06   Fee paid on   29.12.2016
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipHU17.06.2004
AT15.02.2017
CY15.02.2017
CZ15.02.2017
DK15.02.2017
EE15.02.2017
ES15.02.2017
FI15.02.2017
IT15.02.2017
MC15.02.2017
NL15.02.2017
PL15.02.2017
RO15.02.2017
SE15.02.2017
SI15.02.2017
SK15.02.2017
TR15.02.2017
BG15.05.2017
GR16.05.2017
PT15.06.2017
GB17.06.2017
IE17.06.2017
LU17.06.2017
BE30.06.2017
CH30.06.2017
FR30.06.2017
LI30.06.2017
[2020/15]
Former [2019/46]HU17.06.2004
AT15.02.2017
CY15.02.2017
CZ15.02.2017
DK15.02.2017
EE15.02.2017
ES15.02.2017
FI15.02.2017
IT15.02.2017
MC15.02.2017
NL15.02.2017
PL15.02.2017
RO15.02.2017
SE15.02.2017
SI15.02.2017
SK15.02.2017
BG15.05.2017
GR16.05.2017
PT15.06.2017
GB17.06.2017
IE17.06.2017
LU17.06.2017
BE30.06.2017
CH30.06.2017
FR30.06.2017
LI30.06.2017
Former [2019/31]HU17.06.2004
AT15.02.2017
CZ15.02.2017
DK15.02.2017
EE15.02.2017
ES15.02.2017
FI15.02.2017
IT15.02.2017
MC15.02.2017
NL15.02.2017
PL15.02.2017
RO15.02.2017
SE15.02.2017
SI15.02.2017
SK15.02.2017
BG15.05.2017
GR16.05.2017
PT15.06.2017
GB17.06.2017
IE17.06.2017
LU17.06.2017
BE30.06.2017
CH30.06.2017
FR30.06.2017
LI30.06.2017
Former [2018/39]AT15.02.2017
CZ15.02.2017
DK15.02.2017
EE15.02.2017
ES15.02.2017
FI15.02.2017
IT15.02.2017
MC15.02.2017
NL15.02.2017
PL15.02.2017
RO15.02.2017
SE15.02.2017
SI15.02.2017
SK15.02.2017
BG15.05.2017
GR16.05.2017
PT15.06.2017
GB17.06.2017
IE17.06.2017
LU17.06.2017
BE30.06.2017
CH30.06.2017
FR30.06.2017
LI30.06.2017
Former [2018/29]AT15.02.2017
CZ15.02.2017
DK15.02.2017
EE15.02.2017
ES15.02.2017
FI15.02.2017
IT15.02.2017
MC15.02.2017
NL15.02.2017
PL15.02.2017
RO15.02.2017
SE15.02.2017
SI15.02.2017
SK15.02.2017
BG15.05.2017
GR16.05.2017
PT15.06.2017
GB17.06.2017
IE17.06.2017
LU17.06.2017
CH30.06.2017
FR30.06.2017
LI30.06.2017
Former [2018/23]AT15.02.2017
CZ15.02.2017
DK15.02.2017
EE15.02.2017
ES15.02.2017
FI15.02.2017
IT15.02.2017
MC15.02.2017
NL15.02.2017
PL15.02.2017
RO15.02.2017
SE15.02.2017
SI15.02.2017
SK15.02.2017
BG15.05.2017
GR16.05.2017
PT15.06.2017
GB17.06.2017
IE17.06.2017
LU17.06.2017
CH30.06.2017
LI30.06.2017
Former [2018/21]AT15.02.2017
CZ15.02.2017
DK15.02.2017
EE15.02.2017
ES15.02.2017
FI15.02.2017
IT15.02.2017
MC15.02.2017
NL15.02.2017
PL15.02.2017
RO15.02.2017
SE15.02.2017
SI15.02.2017
SK15.02.2017
BG15.05.2017
GR16.05.2017
PT15.06.2017
GB17.06.2017
LU17.06.2017
CH30.06.2017
LI30.06.2017
Former [2018/14]AT15.02.2017
CZ15.02.2017
DK15.02.2017
EE15.02.2017
ES15.02.2017
FI15.02.2017
IT15.02.2017
MC15.02.2017
NL15.02.2017
PL15.02.2017
RO15.02.2017
SE15.02.2017
SI15.02.2017
SK15.02.2017
BG15.05.2017
GR16.05.2017
PT15.06.2017
Former [2018/11]AT15.02.2017
CZ15.02.2017
DK15.02.2017
EE15.02.2017
ES15.02.2017
FI15.02.2017
IT15.02.2017
MC15.02.2017
NL15.02.2017
PL15.02.2017
RO15.02.2017
SE15.02.2017
SK15.02.2017
BG15.05.2017
GR16.05.2017
PT15.06.2017
Former [2017/50]AT15.02.2017
CZ15.02.2017
DK15.02.2017
EE15.02.2017
ES15.02.2017
FI15.02.2017
IT15.02.2017
NL15.02.2017
PL15.02.2017
RO15.02.2017
SE15.02.2017
SK15.02.2017
BG15.05.2017
GR16.05.2017
PT15.06.2017
Former [2017/49]AT15.02.2017
CZ15.02.2017
EE15.02.2017
ES15.02.2017
FI15.02.2017
IT15.02.2017
NL15.02.2017
RO15.02.2017
SE15.02.2017
SK15.02.2017
BG15.05.2017
GR16.05.2017
PT15.06.2017
Former [2017/48]AT15.02.2017
CZ15.02.2017
ES15.02.2017
FI15.02.2017
NL15.02.2017
SE15.02.2017
BG15.05.2017
GR16.05.2017
PT15.06.2017
Former [2017/42]AT15.02.2017
ES15.02.2017
FI15.02.2017
NL15.02.2017
SE15.02.2017
BG15.05.2017
GR16.05.2017
PT15.06.2017
Documents cited:Search[Y]WO9858956  (LUDWIG INST CANCER RES [US]);
 [XYI]WO0130382  (AVENTIS PASTEUR [CA], et al);
 [A]WO0228429  (ALLECURE CORP [US], et al);
 [A]WO03011331  (ISIS INNOVATION [GB], et al);
ExaminationWO02080648
by applicantWO9902183
 US2002007173
 US2003026231
 US2003046714
 US2003138808
 US2003215425
 US2003220239
 US2003228634
 WO2004018666
 WO2004022709
 US6709844
 WO1998US14289
 US19990380534
 US20000561571
 US20000560465
 US20000561074
 US20000561572
 US20010776232
 US20010282211
 US20010337017
 US20010026066
 US20020363210
 US20020094699
 US20020117937
 US20020409123
 US20020255568
 US20020292413
 US20030479393
 US20030479554
 US20030657022
 WO2003US27706
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.